Apr 162011

Death, long hospital stays, and treatment failures are more likely when vancomycin is used for MRSA bacteremia with minimum inhibitory concentrations (MIC) > 1 mcg/mL. Lubin et al propose a clinical prediction rule to predict relative vancomycin resistance, based on a retrospective analysis of 272 patients with MRSA bacteremia at Tufts. Oversimplifying slightly: Having less than two risk factors (age > 50; prior receipt of vanco; prior MRSA bacteremia; chronic liver disease, or a nontunneled venous catheter) had a 91% negative predictive value for having an MRSA strain with MIC > 1 (relative vancomycin resistance). Having 2 or more factors had a positive predictive value of only 30%, though. There was no prospective validation cohort. Clin Infect Dis 2011;52:997-1002.

Liked this post? Get a weekly email update, and explore our library of clinical guidelines, practice updatesreview articles. and board review questions.

PulmCCM is an independent publication not affiliated with or endorsed by any other organization, society or journal referenced on the website. (Terms of Use | Privacy Policy)

Authors: contribute your work in a guest post.


Predicing vancomycin failure in MRSA bacteremia